Ceva Animal Health, the world’s fifth-largest animal health company, has announced a renewed shareholding structure designed to accelerate its global growth and innovation.
Under the leadership of Dr. Marc Prikazsky, Ceva’s management has reaffirmed its commitment to independence by retaining the majority of voting rights. The company continues to be supported by its long-term backers, known as the “Friends of Ceva,” along with strategic investors like Temasek, PSP Investments, Sofiprotéol (Avril Group), and Mitsui & Co.
In a move to fuel future expansion, Ceva has welcomed new capital from healthcare investment specialists Mérieux Institute and ARCHIMED. ARCHIMED, led by veterinarian Dr. Denis Ribon, brings a focus on international development and research acceleration. Canadian pension fund PSP Investments has also significantly increased its stake.
Ceva, which operates in 47 countries with 7,000 employees, is a global leader in veterinary vaccines and animal health solutions. With revenues reaching €1.77 billion in 2024, the company continues to invest heavily in preventive medicine, gene therapy, and environmental sustainability—key areas for producers focused on herd health and long-term viability.
“We’re proud to strengthen our ownership while opening the door to new strategic investors. This allows us to expand innovation, support food security, and address emerging animal health challenges,” said Dr. Prikazsky. “Our mission remains clear: to build stronger links between animal, human, and environmental health.”
Ceva extended thanks to its advisors—Lazard, Rothschild, Weil, and Callisto—for their role in guiding the restructuring.
